It is a pleasure for us to announce that BORN2GROW GmbH & Co. KG, a subsidiary of Zukunftsfonds Heilbronn (ZFHN), invests in our company and technology. Since almost 20 years the ZFHN successfully consults and accompanies start-up technologies and companies. BORN2GROW is the second investor in
Read in the press article from the "Aachener Zeitung" why human Platelet Lysate is still unusual but morally inoffensive PL BioScience produces human Platelet Lysate (hPL) as a cell culture supplement. This is still unusual because using the controversial Fetal Bovine Serum (FBS) for cell culture
PL BioScience will be at the virtual Cell Therapy Manufacturing & Gene Therapy Congress 2020 Also this year from October 19 to 22, 2020 we will participate the international congress for Cell & Gene Therapy The year 2020 is a special year and we are glad to
The TechVision Fonds brings in new capital in PL BioScience We are proud to announce that with the support of SilverSky LifeSciences we successfully managed to convince the TechVision Fonds to invest in our start-up business. The TechVision Fonds, managed by the S-UBG group, supports innovative start-up
